This is the third indication under clinical development for soquelitinib, which is also in a registrational Phase 3 trial for peripheral T cell lymphoma (PTCL) and a Phase 1 trial for atopic ...

Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

Do you know about this pathbreaking cancer therapy?.